NYSE · Healthcare
Organon & Co. (OGN)
As-reported financials and recent SEC filings for Organon & Co., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$6.22B
Net income
$187.0M
Net margin
3.0%
Diluted EPS
$0.72
ROE
24.9%
P/E (TTM)
14.5×
Market cap
$3.55B
Debt / equity
11.5×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.22B | $6.40B | $6.26B | $6.17B | $6.30B |
| Gross profit | $3.31B | $3.71B | $3.75B | $3.88B | $3.92B |
| Operating income | — | — | — | — | — |
| Net income | $187.0M | $864.0M | $1.02B | $917.0M | $1.35B |
| Diluted EPS | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
DEFM14A2026-06-17
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →Go deeper on OGN
Search Organon & Co.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.